Quantitative Prediction of CYP3A4- and CYP3A5-Mediated Drug Interactions
© 2019 Eli Lilly and Company. Clinical Pharmacology & Therapeutics © 2019 American Society for Clinical Pharmacology and Therapeutics. We verified a physiologically-based pharmacokinetic (PBPK) model to predict cytochrome P450 3A4/5-mediated drug-drug interactions (DDIs). A midazolam (MDZ)–ket...
Saved in:
Main Authors: | Yingying Guo, Aroonrut Lucksiri, Gemma L. Dickinson, Raj K. Vuppalanchi, Janna K. Hilligoss, Stephen D. Hall |
---|---|
Format: | Journal |
Published: |
2020
|
Subjects: | |
Online Access: | https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85073807563&origin=inward http://cmuir.cmu.ac.th/jspui/handle/6653943832/68538 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Institution: | Chiang Mai University |
Similar Items
-
Physiologically based pharmacokinetic model of mechanism-based inhibition of CYP3A by clarithromycin
by: Sara K. Quinney, et al.
Published: (2018) -
Ergotism and factitious hypotension associated with interaction of ergotamine with CYP3A4 inhibitors
by: S. Srisuma, et al.
Published: (2018) -
CYP2B6 18492T→C polymorphism compromises efavirenz concentration in coinfected HIV and tuberculosis patients carrying CYP2B6 haplotype *1/*1
by: Weerawat Manosuthi, et al.
Published: (2018) -
Impact of pharmacogenetic markers of CYP2B6, clinical factors, and drug-drug interaction on efavirenz concentrations in HIV/tuberculosis-coinfected patients
by: Weerawat Manosuthi, et al.
Published: (2018) -
In vivo evaluation of coumarin and nicotine as probe drugs to predict the metabolic capacity of CYP2A6 due to genetic polymorphism in Thais.
by: Sompop Peamkrasatam, et al.
Published: (2018)